Market Overview

Pete Najarian Sees Unusual Options Activity In SPDR S&P Biotech

Share:
Related XBI
Analysis: White House Takes Bully Pulpit Approach On Drug Pricing Reform, Congress Unlikely To Act
'Right To Try' Law Signed By Trump Increases Patient Access To Experimental Drugs
Alzheimer's And Infectious Disease: For Real (Seeking Alpha)

On CNBC's "Fast Money Halftime Report", Pete Najarian spoke about high options volume in SPDR S&P Biotech (ETF) (NYSE: XBI).

He said that around 22,000 contracts of the November 90 calls were bought for $2. It's unusual to see that much volume in SPDR S&P Biotech, explained Najarian. The trade breaks even at $92 or 4.26 percent above the current market price. Najarian decided to follow the trade.

Posted-In: CNBC Fast Money Halftime Report Pete NajarianOptions Markets Media ETFs

 

Related Articles (XBI)

View Comments and Join the Discussion!